Genotropin

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Short Stature

Conditions

Short Stature

Trial Timeline

Dec 1, 2003 → Dec 1, 2017

NCT ID

NCT02879747

About Genotropin

Genotropin is a phase 2/3 stage product being developed by Pfizer for Short Stature. The current trial status is completed. This product is registered under clinical trial identifier NCT02879747. Target conditions include Short Stature.

What happened to similar drugs?

5 of 15 similar drugs in Short Stature were approved

Approved (5) Terminated (2) Active (10)

🔄somatropin + leuprorelinEli LillyPhase 3

✅Growth HormoneEli LillyApproved

🔄Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3

🔄Saizen® + Saizen®MerckPhase 3

✅Somatotropin growth hormone recombinant humanPfizerApproved

✅Genotropin (somatropin)PfizerApproved

🔄Genotropin + GenotropinPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02879747	Phase 2/3	Completed	Dec 1, 2003	Dec 1, 2017	Short Stature
NCT00420251	Phase 3	Completed	Mar 1, 1996	Jul 1, 2006	Juvenile Idiopathic Arthritis
NCT00174408	Phase 3	Completed	Mar 1, 1990	Feb 1, 2005	Growth Disorders

Competing Products

20 competing products in Short Stature

See all competitors

Product	Company	Stage	Hype Score
somatropin + leuprorelin	Eli Lilly	Phase 3	40
Growth Hormone	Eli Lilly	Approved	35
Pancreatic Enzyme	AbbVie	Phase 2	35
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone	AstraZeneca	Phase 3	40
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)	Merck	Phase 1	29
Saizen® + Saizen®	Merck	Phase 3	40
r-metHuLeptin	Amgen	Phase 1	29
Somapacitan + Norditropin®	Novo Nordisk	Phase 2	39
Somatotropin growth hormone recombinant human	Pfizer	Approved	43
Genotropin (somatropin)	Pfizer	Approved	43
Genotropin + Genotropin	Pfizer	Phase 3	40
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment	Pfizer	Approved	43
glepaglutide	Zealand Pharma	Phase 3	41
Glepaglutide	Zealand Pharma	Phase 3	41
ZP1848	Zealand Pharma	Phase 2	32
glepaglutide + Placebo	Zealand Pharma	Phase 3	37
Glepaglutide	Zealand Pharma	Phase 3	37
Glepaglutide 10 mg	Zealand Pharma	Phase 3	44
Glepaglutide	Zealand Pharma	Phase 3	44
Nutropin [Somatropin (rDNA origin) for injection]	Ipsen	Approved	32